FindTrial
Sign In

Lidocaine medicated plaster in patients with CRPS

Efficacy of Lidocaine medicated plaster in patients with CRPS: a pilot-study - Lidocaine medicated plaster in CRPS

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2011-002212-81-AT
Enrollment
Unknown
Registered
2011-10-19
Start date
2011-11-09
Completion date
Unknown
Last updated
2015-08-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Complex Regional Pain Syndrome - CRPS lasting longer than 6 month

Interventions

Trade Name: Versatis 5 % medicated plaster Product Name: Versatis 5% Medicated Plaster Product Code: Versatis 5% Mediacted Plaster Pharmaceutical Form: Medicated plaster INN or Proposed INN: LIDOCAINE

Sponsors

Klinik für Physikalische Medizin und Rehabilitation, Medizinische Universität Wien
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: CRPS typ I of the upper limb, lasting longer than 6 months Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 20 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 5

Exclusion criteria

Exclusion criteria: thrombosis, inflammation, edema, severe dysfunction of the heart, liver and kidney, pregnancy, diabetic neuropathia, peripheral lesion of the nervous system, diseases of the central nervous system, diseases of the contralateral arm, contraindication to the physical therapy, allergy or hypersensitivity to the lidocaine-patch

Design outcomes

Primary

MeasureTime frame
Main Objective: Does a Lidocaine medicated plaster in combination with physical therapy increase the armfunction (Radboud skills questionnaire) and normalize armtemperature (infra-red thermography) in patients with CRPS. ;Secondary Objective: Pain, allodynia, sensory dysfunctions;Primary end point(s): Radboud skills questionnaire, infra-red thermography;Timepoint(s) of evaluation of this end point: week 0, week 5, week 12—

Secondary

MeasureTime frame
Secondary end point(s): pain, allodynia, sensory disturbancies;Timepoint(s) of evaluation of this end point: week 0, week 5, week 12—

Countries

Austria

Contacts

Public ContactOthmar Schuhfried

Klinik für Physikalische Medizin und Rehabilitation, Medizinische Universität Wien

othmar.schuhfried@meduniwien.ac.at00431404002308

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026